AMAG gets FDA warning for misbranding drugs

Wed, 10/27/2010 - 12:34pm
Mass High Tech: The Journal of New England Technology

The FDA has sent a letter to the CEO of AMAG Pharmaceuticals Inc., warning the company that websites promoting two FDA-approved products omit information about risks associated with the drug products. The regulator says the omissions amount to a misbranding of the drugs, in violation of FDA rules.

One of the products in question is Feraheme, an iron replacement therapy for patients with kidney disease, that was approved in July of 2009. The other is GastroMARK, which is a diagnostic tool for oral use with magnetic resonance imaging to enhance the delineation of the bowel to distinguish it from organs and tissues that are adjacent to the upper regions of the gastrointestinal tract.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.